|
1
|
Wang S, Li H, Wang J, Wang D, Yao A and Li
Q: Prognostic and biological significance of microRNA-127
expression in human breast cancer. Dis Markers. 2014:4019862014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu Y, Xu K and Yagüe E: miR-218 targets
survivin and regulates resistance to chemotherapeutics in breast
cancer. Breast Cancer Res Treat. 151:269–280. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su CM, Wang MY, Hong CC, Chen HA, Su YH,
Wu CH, Huang MT, Chang YW, Jiang SS, Sung SY, et al: miR-520 h is
crucial for DAPK2 regulation and breast cancer progression.
Oncogene. 35:1134–1142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Negrini M and Calin GA: Breast cancer
metastasis: A microRNA story. Breast Cancer Res. 10:2032008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang Q, Gumireddy K, Schrier M, le Sage
C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al:
The microRNAs miR-373 and miR-520c promote tumour invasion and
metastasis. Nat Cell Biol. 10:202–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moreno-Moya JM, Vilella F and Simón C:
MicroRNA: Key gene expression regulators. Fertil Steril.
101:1516–1523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Tang H, Chen J, Song C, Yang L, Liu
P, Wang N and Xie X, Lin X and Xie X: MicroRNA-101 inhibits cell
progression and increases paclitaxel sensitivity by suppressing
MCL-1 expression in human triple-negative breast cancer.
Oncotarget. 6:20070–20083. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
14
|
Wang G, Zhu S, Gu Y, Chen Q, Liu X and Fu
H: MicroRNA-145 and MicroRNA-133a Inhibited Proliferation,
Migration, and Invasion, while promoted apoptosis in hepatocellular
carcinoma cells via targeting FSCN1. Dig Dis Sci. 60:3044–3052.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang W, Ren F, Wu Q, Jiang D, Li H and Shi
H: MicroRNA-497 suppresses angiogenesis by targeting vascular
endothelial growth factor A through the PI3K/AKT and MAPK/ERK
pathways in ovarian cancer. Oncol Rep. 32:2127–2133.
2014.PubMed/NCBI
|
|
16
|
Marini F, Luzi E and Brandi ML: MicroRNA
role in thyroid cancer development. J Thyroid Res. 2011:4071232011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong LL, Chen LM, Wang WM and Zhang LM:
Decreased expression of microRNA-124 is an independent unfavorable
prognostic factor for patients with breast cancer. Diagn Pathol.
10:452015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiao J, Jing ZC, Ellinor PT, Liang D,
Zhang H, Liu Y, Chen X, Pan L, Lyon R, Liu Y, et al: MicroRNA-134
as a potential plasma biomarker for the diagnosis of acute
pulmonary embolism. J Transl Med. 9:1592011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zha R, Guo W, Zhang Z, Qiu Z, Wang Q, Ding
J, Huang S, Chen T, Gu J, Yao M and He X: Genome-wide screening
identified that miR-134 acts as a metastasis suppressor by
targeting integrin β1 in hepatocellular carcinoma. PLoS One.
9:e876652014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niu CS, Yang Y and Cheng CD: MiR-134
regulates the proliferation and invasion of glioblastoma cells by
reducing Nanog expression. Int J Oncol. 42:1533–1540.
2013.PubMed/NCBI
|
|
21
|
Wang J, Li J, Guo F and Yan Y:
MicroRNA-133a inhibits the malignant behavior of glioma via
downregulation of matrix metallopeptidase 9. Mol Med Rep.
13:3220–3226. 2016.PubMed/NCBI
|
|
22
|
Yang Z, Han Y, Cheng K, Zhang G and Wang
X: miR-99a directly targets the mTOR signalling pathway in breast
cancer side population cells. Cell Prolif. 47:587–595. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu ZS, Wang CQ, Xiang R, Liu X, Ye S, Yang
XQ, Zhang GH, Xu XC, Zhu T and Wu Q: Loss of miR-133a expression
associated with poor survival of breast cancer and restoration of
miR-133a expression inhibited breast cancer cell growth and
invasion. BMC Cancer. 12:512012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012.PubMed/NCBI
|
|
25
|
Schratt GM, Tuebing F, Nigh EA, Kane CG,
Sabatini ME, Kiebler M and Greenberg ME: A brain-specific microRNA
regulates dendritic spine development. Nature. 439:283–289. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yin C, Wang PQ, Xu WP, Yang Y, Zhang Q,
Ning BF, Zhang PP, Zhou WP, Xie WF, Chen WS and Zhang X: Hepatocyte
nuclear factor-4α reverses malignancy of hepatocellular carcinoma
through regulating miR-134 in the DLK1-DIO3 region. Hepatology.
58:1964–1976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han L, Wen Z, Lynn RC, Baudet ML, Holt CE,
Sasaki Y, Bassell GJ and Zheng JQ: Regulation of chemotropic
guidance of nerve growth cones by microRNA. Mol Brain. 4:402011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y
and Yu W: miR-134 inhibits epithelial to mesenchymal transition by
targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett.
586:3761–3765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo L, Liu Y, Bai Y, Sun Y, Xiao F and Guo
Y: Gene expression profiling of drug-resistant small cell lung
cancer cells by combining microRNA and cDNA expression analysis.
Eur J Cancer. 46:1692–1702. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu CJ, Shen WG, Peng SY, Cheng HW, Kao
SY, Lin SC and Chang KW: miR-134 induces oncogenicity and
metastasis in head and neck carcinoma through targeting WWOX gene.
Int J Cancer. 134:811–821. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tao S, Wang S, Moghaddam SJ, Ooi A,
Chapman E, Wong PK and Zhang DD: Oncogenic KRAS confers
chemoresistance by upregulating NRF2. Cancer Res. 74:7430–7441.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parada LF, Tabin CJ, Shih C and Weinberg
RA: Human EJ bladder carcinoma oncogene is homologue of Harvey
sarcoma virus ras gene. Nature. 297:474–478. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zuber J, Tchernitsa OI, Hinzmann B,
Schmitz AC, Grips M, Hellriegel M, Sers C, Rosenthal A and Schäfer
R: A genome-wide survey of RAS transformation targets. Nat Genet.
24:144–152. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Crespo P and León J: Ras proteins in the
control of the cell cycle and cell differentiation. Cell Mol Life
Sci. 57:1613–1636. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu Y, Zhuang Y, Han M, Xu T and Deng K:
Ras promotes cell survival by antagonizing both JNK and Hid signals
in the Drosophila eye. BMC Dev Biol. 9:532009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z,
Li P, Zhang W, Wu H, Feng N, et al: miR-143 decreases prostate
cancer cells proliferation and migration and enhances their
sensitivity to docetaxel through suppression of KRAS. Mol Cell
Biochem. 350:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Haagenson KK and Wu GS: The role of MAP
kinases and MAP kinase phosphatase-1 in resistance to breast cancer
treatment. Cancer Metastasis Rev. 29:143–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dunn KL, Espino PS, Drobic B, He S and
Davie JR: The Ras-MAPK signal transduction pathway, cancer and
chromatin remodeling. Biochem Cell Biol. 83:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Atanaskova N, Keshamouni VG, Krueger JS,
Schwartz JA, Miller F and Reddy KB: MAP kinase/estrogen receptor
cross-talk enhances estrogen-mediated signaling and tumor growth
but does not confer tamoxifen resistance. Oncogene. 21:4000–4008.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Salh B, Marotta A, Matthewson C, Ahluwalia
M, Flint J, Owen D and Pelech S: Investigation of the Mek-MAP
kinase-Rsk pathway in human breast cancer. Anticancer Res.
19:731–740. 1999.PubMed/NCBI
|
|
41
|
Eckert LB, Repasky GA, Ulkü AS, McFall A,
Zhou H, Sartor CI and Der CJ: Involvement of Ras activation in
human breast cancer cell signaling, invasion, and anoikis. Cancer
Res. 64:4585–4592. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lo HW, Hsu SC and Hung MC: EGFR signaling
pathway in breast cancers: From traditional signal transduction to
direct nuclear translocalization. Breast Cancer Res Treat.
95:211–218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kent OA, Fox-Talbot K and Halushka MK:
RREB1 repressed miR-143/145 modulates KRAS signaling through
downregulation of multiple targets. Oncogene. 32:2576–2585. 2013.
View Article : Google Scholar : PubMed/NCBI
|
